Overview

Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

Status:
Recruiting

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

Multicenter, open-label, non randomized, phase 2 trial in resectable gastric or gastroesophageal junction adenocarcinoma: Perioperative Treatment by Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)

Phase:

Phase 2

Details

Lead Sponsor:

Centre Francois Baclesse

Collaborator:

National Cancer Institute, France